(Q36166836)

English

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

C Nabhan

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

D Villines

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

T V Valdez

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

K Tolzien

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

T M Lestingi

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

J D Bitran

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

S M Christner

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

M J Egorin

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

J H Beumer

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

17 July 2012

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

107

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

592-597

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

NCCN clinical practice guidelines in oncology: prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Sorafenib for the treatment of advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3419960

2 October 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

Mechanisms of androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

Metabolism and disposition of imatinib mesylate in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

Safety and efficacy of sorafenib in patients with castrate resistant prostate cancer: a Phase II study

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.312

21 January 2018

Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/22805325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response evaluation criteria in solid tumors (RECIST): new guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/22805325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gene expression correlates of clinical prostate cancer behavior

1 reference

https://pubmed.ncbi.nlm.nih.gov/22805325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2012.312

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36166836&oldid=2198288987"